Ledger.Open graph →
SEC Form D · filed December 15, 2023

Odyssey Therapeutics, Inc

Offering
$106.0M
Sold
$97.1M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Boston, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (20)

Christopher Mayer · Mt Airy, MDDirectorJohn C. Gillam · Wilmington, DEExec · DirectorJeffrey D. Leiden · Boston, MADirectorLorence M. Kim · Boston, MADirectorCarl D. Gordon · Boston, MADirectorPatrick L. Reilly · WALNUT CREEK, CADirectorValerie D. Odegard · Boston, MADirectorM. C. Baum · Boston, MADirectorM. C. Baum · Boston, MADirectorCarl D. Gordon · Boston, MADirectorJeffrey D. Leiden · Boston, MADirectorJill D. Carroll · Boston, MADirectorTravis C. Miller · Wilmington, DEDirectorGary D. Glick · Boston, MAExec · DirectorGary D. Glick · Boston, MAExec · DirectorRoger K. Coit · Walnut Creek, CADirectorLorence M. Kim · Boston, MADirectorAdam Lilling · Venice, CADirectorJill D. Carroll · Boston, MADirectorValerie D. Odegard · Boston, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗